Should You Buy Globus Medical Inc (GMED) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/28
Buy now for a beginner, long-term investor with $50k–$100k. GMED is in a broader uptrend (bullish moving averages) and fundamentals/Street sentiment have improved meaningfully after the strong Q4 preannouncement and multiple price-target hikes. While momentum has cooled short-term (bearish MACD), the stock is sitting near a clear support zone (~90), making the current level (91.83) a reasonable entry for an investor who doesn’t want to wait for a “perfect” dip.
Technical Analysis
Trend/levels: The moving-average stack is bullish (SMA_5 > SMA_20 > SMA_200), which supports a longer-term uptrend. However, momentum has weakened: MACD histogram is negative and expanding (-0.387), suggesting a near-term pullback/sideways phase is possible. RSI(6)=43 is neutral-to-slightly weak (not oversold).
Key levels: Price 91.83 is just below the pivot (92.495). Near-term support is S1 ~90.188 (then S2 ~88.762). Near-term resistance is R1 ~94.802 (then R2 ~96.228). For a long-term buyer, entering near support (~90–92) is attractive versus chasing a breakout.
Intellectia Proprietary Trading Signals
- [AI Stock Picker](module://ai_stock_pick): No signal on given stock today.
- [SwingMax](module://swingmax): No signal on given stock today.
Analyst Ratings and Price Target Trends
Recent trend: Ratings and targets have moved up materially from Nov 2025 through Jan 2026. Multiple firms reiterated Buy/Overweight/Outperform and raised price targets after strong results/preliminary Q4 figures (examples: Piper to $115, Canaccord to $112, TD Cowen initiated Buy $110, several others moved into $100–$106 range). One notable counterpoint is Freedom Capital initiating Hold with an $87 target, arguing much of the organic growth is already reflected.
Wall Street pros: improving revenue trajectory, potential margin expansion (including Nevro-related upside), and runway for continued growth/multiple expansion.
Wall Street cons: execution still needs to improve in specific segments/geographies and the stock may already discount a portion of the near-term improvement.
Wall Street analysts forecast GMED stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GMED is 101 USD with a low forecast of 87 USD and a high forecast of 114 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Wall Street analysts forecast GMED stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GMED is 101 USD with a low forecast of 87 USD and a high forecast of 114 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Current: 91.830
Current: 91.830
